medicate
  • About
    • About Tensive
    • Management team
    • Board of Directors
    • Scientific advisors
  • Unmet need
  • Technology
  • Pipeline
  • Investors & Media
    • Investors
    • Press Releases
    • Events
    • Publications
  • Careers
Contact us

Press Releases in English

  1. Home
  2. Press releases
  3. Archive by category : "Press Releases in English"
  • Alessandro Zeni
  • 0 Comments
Tensive appoints Peter Crosby Chairman as its bioresorbable breast reconstruction scaffold approaches regulatory approval

Milan, Italy – July 8, 2026 – Tensive S.r.l., a clinical-stage advanced biomaterials medical device company, and the developer of […]

Read More
  • Alessandro Zeni
  • 0 Comments
Tensive publishes positive interim pivotal clinical data showing REGENERA™ supports natural breast reconstruction in Updates in Surgery

Milan, Italy – April 15, 2026 – Tensive S.r.l., a clinical-stage advanced biomaterials medical device company developing REGENERA™ bioresorbable scaffolds […]

Read More
  • Alessandro Zeni
  • 0 Comments
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy

Milan, Italy – March 04, 2026 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing REGENERA™ bioresorbable scaffolds […]

Read More
  • Alessandro Zeni
  • 0 Comments
Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction

Milan, Italy – January 8, 2026 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing REGENERA™/SOFTAG™ bioresorbable scaffolds […]

Read More
  • Alessandro Zeni
  • 0 Comments
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA™ / SOFTAG™ breast implant

Press release in italian Milan, Italy – 9 October, 2025 Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing […]

Read More
  • officine
  • 0 Comments
Tensive provides positive clinical updates highlighting potential of REGENERA™ / SOFTAG™ device to transform post-cancer breast reconstruction

Press release in italian Clinical data from two ongoing trials in patients undergoing lumpectomy confirm strong safety profile and growing […]

Read More
  • officine
  • 0 Comments
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Press release in italian Has more than 30 years of experience bringing innovations to market, including one of the world’s […]

Read More
  • officine
  • 0 Comments
Tensive raises €14,000,000 Series A Financing Round led by Panakès Partners SGR to transform breast reconstruction following lumpectomy. Appoints Sanjay Kakkar as Chief Executive Officer

Platform based on innovative polymeric scaffolds applied as bio-absorbable implants Initially being developed in breast cancer reconstruction and breast augmentation […]

Read More
  • officine
  • 0 Comments
Tensive S.r.l. Announces Multi-Center Pivotal Clinical Trial for REGENERA Implant in Post-Lumpectomy Breast Reconstruction

Press release in italian Milan, Italy – 21 October 2024 Tensive S.r.l. is excited to announce the launch of a […]

Read More
  • officine
  • 0 Comments
Tensive is awarded by the European Innovation Council Accelerator for its project REGENERA

Milan, Italy – December 19th, 2022 Tensive S.r.l., the medical technology company pioneering innovative solutions for reconstructive surgery, announces that […]

Read More

Categories

  • Events
  • Press releases
    • Press Releases in English
    • Press Releases in Italian
medicate-footer-logo

The breast implants are under development and are not commercially available.

Quick Links

  • Unmet need
  • Pipeline
  • Our Investors
  • Publications

Contact Us

  • +39 02 5666 0265
  • [email protected]
  • [email protected]
Copyright TENSIVE s.r.l. © 2016-2025 All rights reserved
Via Timavo, 34 20124 Milan (Italy) | Reg. Imprese MI/C.F./VAT 08045870964 | Capital: 42,036.40 | Privacy | Cookies | Credits | Trasparenza